Miglitol
- US FDA: Miglitol
category
- AU: B3
administration
- A10BF02 (WHO)
- US: ℞-only
- (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)
piperidine-3,4,5-triol
- 72432-03-2 Y
- 441314
- 4842
- DB00491 Y
- 390074 Y
- 0V5436JAQW
- D00625 Y
- ChEMBL1561 Y
- DTXSID0023323
- Interactive image
- OCCN1[C@@H]([C@@H](O)[C@H](O)[C@@H](O)C1)CO
- InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 Y
- Key:IBAQFPQHRJAVAV-ULAWRXDQSA-N Y
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.[1]
Miglitol, and other structurally-related iminosugars, inhibit glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect.[2] Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
See also
References
- v
- t
- e
|
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e